RD-ConnectRD-Connect

  • About
    • Introduction to rare diseases
    • Structure
      • Executive Management Committee (EMC)
      • Scientific Advisory Board (SAB)
      • Patient Advisory Council (PAC)
      • Rare Disease Patient and Ethics Council (RD-PEC)
      • Panel for Biobank Assessment
    • Collaborations
  • What we do
    • Data linkage
      • FAIRification of rare disease registries
      • Linked data and ontology task force
      • Ontologies in rare disease registries
    • Omics data
      • Genome-Phenome Analysis Platform
    • Phenotypic data
      • Registry & Biobank Finder for patient registries
      • Registry common data elements
      • Core Implementation Group
    • Biosamples data
      • Registry & Biobank Finder for biobanks
      • Sample Catalogue
      • Biobank assessment process
      • Biobank Assessment Panel
    • Bioinformatic tools
    • Ethical, Legal and Social Issues (ELSI)
      • Sharing of biosamples and data
      • Standards for informed consent
      • Response to the EU General Data Protection Regulation (GDPR)
    • Patient engagement
  • Resources
    • Newsletters
    • Scientific publications
    • Forms and guides
    • Presentations and flyers
    • Periodic activity reports
    • Glossary
  • For Patients and Families
  • News
  • Events
  • Contact
    • Coordination office
    • Contacts Directory
    • Organisations Directory
VISIT THE PLATFORM
  • Home
  • Publication
  • Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy
 

Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy

RD-Connect

An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. Visit the platform:

Go to analysis platform

Go to registries and biobanks catalogue

Go to biosamples catalogue

See all publications

Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy

Author(s): Burch PM, Pogoryelova O, Goldstein R, Bennett D, Guglieri M, Straub V, Bushby K, Lochmuller H, Morris C
Published: September 2, 2015
Journal: Journal of Neuromuscular Diseases 2 (3):241-255
DOI: 10.3233/JND-140066

Go to publication

Abstract:

Background: Identifying translatable, non-invasive biomarkers of muscular dystrophy that better reflect the disease pathology than those currently availablewould aid the development of newtherapies, the monitoring of disease progression and the response
to therapy.

Objective: The goal of this study was to evaluate a panel of serum protein biomarkers with the potential to specifically detect skeletal muscle injury.

Method: Serum concentrations of skeletal troponin I (sTnI), myosin light chain 3 (Myl3), fatty acid binding protein 3 (FABP3) and muscle-type creatine kinase (CKM) proteins were measured in 74 Duchenne muscular dystrophy (DMD), 38 Becker muscular
dystrophy (BMD) and 49 Limb-girdle muscular dystrophy type 2B (LGMD2B) patients and 32 healthy controls.

Results: All four proteins were significantly elevated in the serum of these three muscular dystrophy patient populations when compared to healthy controls, but, interestingly, displayed different profiles depending on the type of muscular dystrophy. Additionally, the effects of patient age, ambulatory status, cardiac function and treatment status on the serum concentrations of the proteins were investigated. Statistical analysis revealed correlations between the serum concentrations and certain clinical endpoints including forced vital capacity in DMD patients and the time to walk ten meters in LGMD2B patients. Serum concentrations of these proteins were also elevated in two preclinical models of muscular dystrophy, the mdx mouse and the golden-retriever muscular dystrophy dog.

Conclusions: These proteins, therefore, are potential muscular dystrophy biomarkers for monitoring disease progression and therapeutic response in both preclinical and clinical studies.

Visit the platform

Go to Genome-Phenome Analysis Platform

Go to Registry & Biobank Finder

Go to Sample Catalogue

Newsletter Signup

Recent news

RD-Connect Genome-Phenome Analysis Platform is an IRDiRC Recommended Resource

Published: April 5, 2018

RD-Connect in press

Published: March 1, 2018

Today is the Rare Disease Day 2018

Published: February 28, 2018

Key RD-Connect, NeurOmics and EURenOmics publication

Published: February 27, 2018

RD-Connect and EURenOmics among the DG Research success stories

Published: February 15, 2018

Social

An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. Visit the platform:

Genome-Phenome Analysis Platform

Analyse and share genomic data

Registry & Biobank Finder

Directory of rare disease biobanks and patient registries

Sample Catalogue

Browse rare disease biosamples stored in biobanks

Sitemap

  • NEWS
  • EVENTS
  • CONTACT
    • Coordination office
    • Contacts Directory
    • Organisations Directory
  • About
    • Introduction to rare diseases
    • Structure
      • Executive Management Committee (EMC)
      • Scientific Advisory Board (SAB)
      • Patient Advisory Council (PAC)
      • Rare Disease Patient and Ethics Council (RD-PEC)
      • Panel for Biobank Assessment
    • Collaborations
  • What we do
    • Data linkage
      • FAIRification of rare disease registries
      • Linked data and ontology task force
      • Ontologies in rare disease registries
    • Omics data
      • Genome-Phenome Analysis Platform
    • Phenotypic data
      • Registry & Biobank Finder for patient registries
      • Registry common data elements
      • Core Implementation Group
    • Biosamples data
      • Registry & Biobank Finder for biobanks
      • Sample Catalogue
      • Biobank assessment process
      • Biobank Assessment Panel
    • Bioinformatic tools
    • Ethical, Legal and Social Issues (ELSI)
      • Sharing of biosamples and data
      • Standards for informed consent
      • Response to the EU General Data Protection Regulation (GDPR)
    • Patient engagement
  • Resources
    • Newsletters
    • Scientific publications
    • Forms and guides
    • Presentations and flyers
    • Periodic activity reports
    • Glossary
  • For Patients and Families
  • News
  • Events
  • Contact
    • Coordination office
    • Contacts Directory
    • Organisations Directory

Quick links

  • Genome-Phenome Analysis Platform
  • Registry & Biobank Finder
  • Sample Catalogue

Get social

Newsletter sign up

Sign up to our newsletter

RD-Connect

RD-Connect coordination team
Institute of Genetic Medicine
University of Newcastle upon Tyne
International Centre for Life
Newcastle upon Tyne
NE1 3BZ
United Kingdom

Email: Libby Wood (Project Manager)

T: +44 191 241 8621
F: +44 191 241 8770

TOP
/* ----------------------------------------- */ /* Content Template: Loop item in Recent News - start */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* Content Template: Loop item in Recent News - end */ /* ----------------------------------------- */